3D Printing of Pharmaceuticals: A New Era of Personalized Medicine and On-Demand Drug Manufacturing

Dornala Chaitanya Dixit [1], Shaik Mahammad Rafi [2], M.Sri Ramachandra [3], B.V.Ramana [4]
[1]*Department of Pharmaceutical Analysis, Dr. K. V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool-518218, Andhra Pradesh, India*
[2]*Student, Dr. K. V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool-518218, Andhra Pradesh, India*
[3] *M.Sri Ramachandra M. PHARM, PhD Department of Pharmacology, Dr. K. V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool-518218, Andhra Pradesh, India*
[4] *B.V. Ramana Professor & Principal, Department of Pharmaceutics, Dr. K V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool-518218, Andhra Pradesh, India*

Abstract- Three-dimensional printing (3DP) or additive manufacturing has been one of the most disruptive technologies of the 21st century. Ever since stereo lithography was introduced by Chuck Hull in 1986, several methods such as selective laser sintering, fused deposition modeling, and binder jetting have been created, and each of them widened the application of 3DP. Initially used for prototyping and industrial design, 3DP now has urgent uses in healthcare and the pharmaceutical sciences. The technology allows for the construction of intricate structures with high accuracy, patient-specific dosage forms, on-demand production, and drug delivery systems with tailored release profiles. 3DP innovations include Polypills, tablets that are chewable or Braille-imprinted, and implants with active pharmaceutical ingredients. These abilities create new opportunities in drug discovery, preclinical screening, and clinical practice by reducing the cost of development, decreasing the rate of drug failure, and increasing patient compliance. In the pharmaceutical industry, 3DP has a huge economic and logistical advantage by decentralizing manufacturing, minimizing storage and transport requirements, and allowing immediate response to patient demand. But despite this, there are challenges such as limited pharmaceutical-grade printable materials, quality control problems, regulatory doubts, and production scalability. These hurdles notwithstanding, ongoing advances in material science, printer technology, and digital manufacturing, coupled with changing regulatory environments, should drive clinical take-up. In general, 3DP is a paradigm shift from conventional mass production to tailored medicine. By closing the loop between digital design and physical fabrication, it has the potential to transform pharmaceutical development and delivery in the very near future.

Keywords: 3D Printing(3DP) / Additive Manufacturing, Patient-specific dosage, Tailored drug release, Polypills, Chewable / Braille tablets, Implants with APIs, On-demand production, Decentralized manufacturing, Cost reduction, Regulatory challenges, Quality control.

1. INTRODUCTION

Three-dimensional printing (3DP) can create a paradigm shift in medicine design, manufacture, and usage. Civilization has witnessed intermittent revolutionary transformations in its long past as a result of revolutionary changes known as industrial revolutions. Industrial revolutions have been ushered in by historical events such as the invention of steam-powered engine and mechanized textile mills [1]. Industrial revolutions of a second order resulted from tapping into electrical power to achieve mass production [2], and industrial revolutions of a third order from automation [3]. Now automated and customized systems consisting of cloud computing, Internet of Things (IoT), and 3DP close gaps between virtual as well as real worlds [4].

Currently, 3DP is driving the next industrial revolution. It is a production technique that creates customized objects by depositing layer upon layer of material. Without the drawbacks of conventional tools, 3DP does this through machine and digital technology. Because it deposits material, it is possible to make intricate objects quickly and efficiently with minimal waste [5]. Moreover, computerized object drawings can be stored, transmitted, and varied without much labor or space.

3DP has applications across various industries, including aviation, automobiles, medicine, dentistry, art, jewelry, and footwear [6]. In the pharmaceutical industry, drug development is a multi-step process that consumes extensive resources and time. Since the 1960s, few manufacturing innovations have occurred. Recently, 3DP has opened modern avenues to revolutionize this sector. Specifically, 3DP can print "print lets"—3D-printed solid oral dosage forms such as tablets and capsules. This multidisciplinary tool can be applied to all stages of drug development, enhancing the quality of treatment.

In our earlier review, we provided an account of motives as well as possible applications of 3DP in clinical practice and research, along with challenges and obstacles [7]. This review is centered on technical considerations and presents an overview of opportunities that 3DP presents along drug discovery to testing to drug manufacture to drug dispensing, addressing technological challenges of pharmaceutical applications.

2. LITERATURE REVIEW

1. Salama et al., 2025 – Economical approach to produce small batches of personalized medicine through 3D printing.
2. Zema et al., 2023 – Enables customized devices and drugs through faster, cheaper production; it is vulnerable to small-batch inefficiency and regulatory challenges.
3. Pawar et al., 2022 – Deals with drug and polymer choice, technology, clinical application, and industrial feasibility.
4. Christos I. and others, 2022 - Sees decentralized manufacturing in hospitals, pharmacies, and homes. Main challenges are: regulation, quality assurance, drug shortages, and public acceptance.
5. Trenfield et al., 2021 – HIGHLIGHTS small-batch personalized medicine production from pre-clinical research to clinical application.
6. Vaz et al., 2021 – 3DP as a critical enabler of personalized medicine, e.g., multi-drug polypills.

3. HISTORY OF 3D PRINTING

- In 1970s: Initial publications and patents relating to computer-assisted additive manufacture [8].
- 1984: Stereo lithography (SLA) was invented and patented by Chuck Hull utilizing UV-polymerized resins and later commercially offered by 3D Systems
- In 1986, Carl Deckard created Selective Laser Sintering (SLS) [9].
- In 1989, Scott and Lisa Crump discovered Fused Deposition Modeling (FDM). Emanuel Sachs created binder jetting at MIT.
- Hans Langer discovered Direct Metal Laser Sintering in 1989.

3.1 Definition and Technology of 3D Printing

3DP produces objects by depositing layers of material such as ceramics, liquids, powders, metals, plastics, or living cells from a CAD drawing [10,11]. Alternatively referred to as rapid prototyping (RP) or solid freeform fabrication as some would attribute it to be, 3DP has transformed manufacture by reducing cost and time and enabling sophisticated biomedical applications.

3.2 Earlier Ideas and 3D Printing in India

•In 19th Century: Charles Wheatstone developed stereoscopy (1838).
•1952: First 3D film, "Bwana Devil," released.
•1986: Charles Hull patented the initial 3D printer.
• India: Home-made 3D printers emerged in mid-2000 from companies like Divide by Zero and Alter Technologies. They were first used in jewelry and medical fields.

3D Printing to Help Develop New Medicines
•Averts drug failure and loss of money in initial development stages [1].
3DP builds APIs and tiny reactions by RepRap printers [2].
•Uses animal and human tissues for testing toxicity and studying metabolism.

• Contribute to medical and therapeutic research; most up-to-date developments are Vivo Sims from Organovo 3D bioprinting (April 2025).

3.3. Types of 3D Printing:
•Thermal Inkjet Printing: Non-contact deposit technique of material on a substrate used in tissue engineering and bioprinting [12].
• Selective Laser Sintering (SLS): Utilizes a laser to sinter powders; excellent to create highly detailed ceramic, metal, and plastic products [13].
•Fused Deposition Modeling (FDM): Extrudes molten polymers; relatively inexpensive and most common [14].
•Stereo lithography (SLA): UV curing of photopolymer resins to create high.
•Binder Jetting (BJ): Sprays a liquid binder onto a layer of powder to produce customized tablets.

3.4 Individualized Medicine and Tailor-made Drug Production
•Personalized dosing: Individualize drug dosing to suit specific patient needs (children, ger.
• Tailored release profiles: Allows immediate, constant, controlled, or burst release.
•Polypills: Multiple drugs of different release patterns combined.
•On-demand manufacture: Manufacturing goods as needed in hospitals, drugstores, or residences.
•Patient-focused designs: Tailored shape, color, taste; e.g., Br.
•Improved drug development: Rapid testing decreases clinical trial time and expenditures.

4. RELEVANT 3D PRINTING METHODS IN MEDICAL PRACTICE

Technology:
- Fused Deposition Modeling (FDM): Thermoplastics Custom drug release, cost-effective requires pre-filament preparation
- Direct Powder Extrusion (DPE): Powder mixtures High drug content, no solvent
- Semi-Solid Extrusion (SSE): Gels, pastes Temperature-sensitive drugs Limited mechanical strength
- Selective Laser Sintering (SLS): Powders machining of fine details without any supports
  Binder Jetting Powders + liquid binder versatile release profiles
- Stereo lithography (SLA): Photosensitive resins High resolution Material constraints

5. PROBLEMS AND FUTURE DIRECTIONS

•Technological limitations: Nozzle clogging, drug degradation, structural flaws.
•Material choice: Scarcity of biocompatible, stable material.
•Quality control: Standardized dosages and structure.
•Regulatory Frameworks: Policies for customized and distributed production required.
•Cost and scalability: Scalability is restricted to high-volume.
•IP and counterfeiting: Dangers from easy copying.
•Clinical integration: Requires skilled workers and adequate systems.
Innovations in materials, print methods, and AI design will most likely remedy current challenges. Institutions like the FDA are creating rules relating to safe and efficient use.

6. ECONOMICAL AND LOGISTICAL BENEFITS

•Decentralized manufacturing: Reduces transport, storage costs, and carbon footprint [15].
•Run-level customization: Enables rapid responses to patient requests [16].
•Diminished API waste: This is relevant to orphan drugs and expensive drugs [17].
The 3DP allows for on-demand manufacture, controlled dosing, challenging drug geometries, and multilayer systems of drug delivery. Incorporation into pharmacy-based manufacture can improve patient safety and compliance while decreasing time and material wasted.

7. APPLICATIONS

7.1 Eye Inserts and Tear Duct Plugs
•Ciprofloxacin-loaded ocular inserts: FDM and hot-melt extrusion; prolonged drug release for 24h.
•Ganciclovir-loaded 3D printed ousters: Confocal laser microscopy verified corneal penetration.

• Dexamethasone punctual plugs: Release drug consistently up to 21 days; cell compatibility enhanced upon post-processing.

7.2 Oral Dosage Forms
• Immediate-release tablets: Albendazole nanocrystals filled using 3DP; improved dissolution and stability [18].
•Fused-deposition modeling: Personalized hydrocortisone and caffeine dose titration [70].
• Direct powder extrusion: Rapidly releasing cannabidiol tablets; suitable for preparing small quantities as required [19].

8. IMPROVEMENT OF DRUG BIOAVAILABILITY AND STABILITY

•Semi-solid extrusion: Fenofibrate lipid tablets maintained their non-crystal form and drug content up to 30 days [20].
•Hydroxypropyl methylcellulose: Prednisolone tablets printed via FDM; microstructure influenced by polymer molecular weight [21].
•Floating devices: Controlled release of domperidone through internal structure design; zero-order kinetics obtained [22].
•GMP scale-up: Acetaminophen tablets transferred successfully from laboratory printers to large commercial printers [23].

8.1 Colon-Targeted Tablets
•PH-responsive 3DP tablets for N-acetyl glucosamine drug delivery; enhanced drug release and processability [81.
•Budesonide pill-in-pill technology for inflammatory bowel disease: Ultra-high precision, controlled release, and patient-preferred replacement of rectal administration [24].

9. CONCLUSION

Three-dimensional printing has transformed from prototyping to a disruptive platform with tremendous influence in healthcare and pharmaceuticals. By virtue of its ability to facilitate intricate customized dosage forms, 3DP augments drug discovery, development, and customized treatment. Benefits include customized dosing, Polypills, production when needed, less waste, saving money, and time. Uses in tissue engineering and regenerative medicine show its possibilities beyond delivering drugs. There are still challenges, such as finding materials, making processes standard, getting regulatory approval, and scaling up.

REFERENCE

[1] Atkeson, A. and Kehoe, P.J. (2001) the Transition to a New Economy after the Second Industrial Revolution. National Bureau of Economic Research Working Paper Series No. 8676.
[2] Zhou, K. et al. (2015) Industry 4.0: Towards future industrial opportunities and challenges. In 2015 12th International Conference on Fuzzy Systems and Knowledge Discovery (FSKD), pp. 2147-2152.
[3] Rajkumar, R. et al. (2010) Cyber-physical systems: the next computing revolution. In Proceedings of the 47th Design Automation Conference, pp. 731-736, ACM.
[4] Campbell, T. et al. (2011) could 3D printing change the world. Technologies, Potential, and Implications of Additive Manufacturing, Atlantic Council, Washington, DC.
[5] Barnatt, C. (2016) 3D Printing: Third Edition, CreateSpace Independent Publishing Platform.
[6] Trenfield, S.J. et al. (2018) 3D Printing Pharmaceuticals: Drug Development to Frontline Care. Trends in Pharmacological Sciences 39 (5), 440-451.
[7] Lipson H. New world of 3-D printing offers “completely new ways of thinking:” Q & A with author, engineer, and 3-D printing expert Hod Lipson. IEEE Pulse. 2013; 4(6):12–14.
[8] Savini A, Savini GG. A short history of 3D printing, a technological revolution just started. 4th IEEE Reg 8 Conf Hist Electrotechnol. 2015. Su A, Al’Aref SJ.
[9] . Prasad LK, Smyth H. 3D printing technologies for drug delivery: a review. Drug Dev Ind Pharm. 2016; 42(7):1019–31.
[10] Gross BC, Erkal JL, Lockwood SY, et al. Evaluation of 3D printing and its potential impact on biotechnology and the chemical sciences. Anal Chem. 2014; 86 (7):3240–3253.

[11] Ursan I, Chiu L, Pierce A. Three-dimensional drug printing: a structured review. J Am Pharm Assoc. 2013; 53(2):136–144.
[12] Hoy MB. 3D printing: making things at the library. Med Ref Serv Q. 2013; 32 (1):94–99.
[13] Mertz L. Dream it, designs it, and prints it in 3-D: what can 3-D printing do for you? IEEE Pulse. 2013; 4(6):15–21.
[14] Khaled SA, Burley JC, Alexander MR, *et al.* 3D printing of tablets containing multiple drugs with defined release profiles. International Journal of Pharmaceutics. 2015; 494:643–50.
[15] Alhnan, M.A. et al. (2016) Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. Pharm Res 33 (8), 1817-1832.
[16] Chen, D. et al. (2015) direct digital manufacturing: definition, evolution, and sustainability implications. Journal of Cleaner Production 107, 615 625.
[17] Norman, J. et al. (2017) a new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews 108, 39-50.
[18] Naguib MJ, Hassan YR, Abd-Elsalam WH (2021) 3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis. Int J Pharm 607:121010.
[19] Xu X, Awwad S, Diaz-Gomez L, Alvarez-Lorenzo C, Brocchini S, Gaisford S et al (2021) 3D printed punctal plugs for controlled ocular drug delivery. Pharmaceutics 13(9):1421.
[20] Xie J, Wang C, Ning Q, Gao Q, Gao C, Gou Z et al (2017) A new strategy to sustained release of ocular drugs by one-step drug-loaded microcapsule manufacturing in hydrogel punctal plugs. Graefes Arch Clin Exp Ophthalmol 255:2173–2184.
[21] Jennotte O, Koch N, Lechanteur A, Rosoux F, Emmerechts C, Beeckman E et al (2023) Feasibility study of the use of a homemade direct powder extrusion printer to manufacture printed tablets with an immediate release of a BCS II molecule. Int J Pharm 646:123506.
[22] Ou YH, Goh WJ, Lim SH (2023) Form & formulation approaches for COntRollable release in 3D printed Colonic targeting (CORR3CT) budesonide tablet. Int J Pharm 635:122680.
[23] Johannesson J, Wu M, Johansson M, Bergström CA (2023) Quality attributes for printable emulsion gels and 3D-printed tablets: towards production of personalized dosage forms. Int J Pharm 646:123413.
[24] Larsen BS, Kissi E, Nogueira LP, Genina N, tho I (2024) Impact of drug load and polymer molecular weight on the 3D microstructure of printed tablets. Eur J Pharm Sci 192:106619.
[25] Seoane-Viaño I, Pérez-Ramos T, Liu J, Januskaite P, Guerra-Baamonde E, González-Ramírez (2024) Visualizing disintegration of 3D printed tablets in humans using MRI and comparison with in vitro disintegration data. J Control Release 365:348–357.